Lattice Biologics Ltd, of Scottsdale, Arizona, is preparing to launch three new products—all featuring the company’s Matrix-Assisted Regeneration (MAR) technology. The three products are Amniotic Tissue Matrix, Demineralized Cortical Fiber, and Viable Cell Allografts.
Three New Biologic Products Launched
1 min read Premium comments
Secondary
Richard D Guyer, M.D., of the Texas Back Institute and a Lattice Biologics Scientific Advisory Board Member, said, “The ability to identify viable cells from non-viable cells promises a new understanding in this class of allograft tissue. It will be interesting to see if viable cells can auto-regulate BMPs (bone morphogenetic proteins) in sufficient levels to induce spinal fusion.”
MarBrane is Lattice Biologics’ first amniotic tissue membrane product harvested from placental tissue. MarBrane was developed for use in advanced wound care, plastic surgery, and pain management, spinal, orthopedic, and ocular indications.
The company maintains that placental tissues are a rich source of proteins, nutrients, carbohydrates, and growth factors that are essential for growth and development. Amniotic tissue, the innermost layer of the placenta, is “immune-privileged” and, as such, rarely evokes an immune response in the human body. Company research has shown that amniotic tissue does not express the Class II antigens that typically evoke an immune response.
One of the three new products, MarBrane is an amniotic tissue matrix allograft, that company officials say offers natural collagen scaffolding that gives structural support to adjacent cells for tissue development. It also, they claim, promotes the migration and proliferation of the patient’s own cells to the site of injury. Placental tissue allografts, they say, present a safe, non-immunologic alternative to synthetic, cadaveric, and animal-derived regenerative products.
The second product, MarGraft, is a demineralized cortical fiber product, which can be molded into various sizes and shapes, including multi-segment strips and boats. These are used widely in spinal fusion.
The third product, MarCell combines multiple proprietary technologies to produce a fully moldable viable cell allograft.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.